DUBLIN, Ireland — Perrigo Co. plc has received approval from the Food and Drug Administration for omeprazole and sodium bicarbonate capsules 20 mg/1100 mg, an over-the-counter medicine for heartburn.

Perrigo said Monday that its product marks the first store-brand launch of an equivalent to Bayer’s Zegerid OTC capsules.

Shipments to retail customers are under way, according to Perrigo. The company said its product will be packaged and marketed as a store-brand or retailer “own label”  item.

“This OTC product approval and launch illustrates Perrigo’s commitment to providing customers and consumers with high-quality value alternatives in important treatment categories,” stated Perrigo chief executive officer John Hendrickson. “Important product launches like the store-brand version of Zegerid OTC are what drive Perrigo’s ability to provide quality affordable health care products to customers and consumers around the world.”

Indicated for the treatment of frequent heartburn, Zegerid OTC employs the dual action of omeprazole, a proton pump inhibitor that lowers the amount of acid in the stomach, and sodium bicarbonate, an antacid that raises the stomach’s pH level prevent the omeprazole from breaking down in stomach acid.

National-brand sales of omeprazole and sodium bicarbonate capsules 20 mg/1100 mg for the 12 months ended in June were $27 million, Perrigo reported.